Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Phase 1 Trials

Boston, Massachusetts

Phase 1 colorectal cancer trials in Boston, MA

54 Phase 1 colorectal cancer studies are recruiting participants at sites in Boston as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.

Call (888) 415-5976
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Boston at a glance

  • 54 studies are recruiting at a site in Boston.
  • By phase: Early Phase 1 (2), Phase 1 (27), Phase 1/2 (25).
  • By sponsor: industry (45), university, hospital or other (9).
  • Most recent update to one of these records: November 17, 2026.

Studies recruiting in Boston

Basic details from each study's public record (the 30 most recently updated of 54). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05786924 · updated
  2. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT06253871 · updated
  3. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06324357 · updated
  4. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital (MG)
    Registry record
    NCT06983743 · updated
  5. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Mass General Brigham Cancer Institute at Massachusetts General Hospital
    Registry record
    NCT07458347 · updated
  6. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07020221 · updated
  7. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07114601 · updated
  8. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07213791 · updated
  9. A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Dana Farber Cancer Institute
    Registry record
    NCT06720987 · updated
  10. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07542704 · updated
  11. A Phase 1 Study of IM-1617 in Participants With Advanced Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Immunome, Inc.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07578571 · updated
  12. A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT07584226 · updated
  13. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Massachusetts General Hospital - Dana Farber
    Registry record
    NCT03526835 · updated
  14. First-in-human Study of 7MW4911 in GI Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Mabwell (Shanghai) Bioscience Co., Ltd.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07216560 · updated
  15. LYL273 for Patients With Relapsed or Refractory mCRC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Lyell Immunopharma, Inc.
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05319314 · updated
  16. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Alterome Therapeutics, Inc.
    Registry record
    NCT06835569 · updated
  17. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study site
    Dana Farber Cancer Institute
    Registry record
    NCT04657068 · updated
  18. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ModeX Therapeutics, An OPKO Health Company
    Study site
    Massachusetts General Hospital
    Registry record
    NCT06239194 · updated
  19. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kura Oncology, Inc.
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06026410 · updated
  20. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Parabilis Medicines, Inc.
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT05919264 · updated
  21. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Bicara Therapeutics
    Study site
    Dana Farber/Partners Cancer Care Inc
    Registry record
    NCT04429542 · updated
  22. A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Dispatch Biotherapeutics
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07544589 · updated
  23. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT04585750 · updated
  24. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #7
    Registry record
    NCT05176483 · updated
  25. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
    Study sites
    Dana-Farber Cancer Insitute · Massachusetts General Hospital
    Registry record
    NCT06625775 · updated
  26. A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT05877599 · updated
  27. A Study of PHN-012 in Patients With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pheon Therapeutics
    Study site
    PHN-012-001 Site
    Registry record
    NCT07127874 · updated
  28. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Neonc Technologies, Inc.
    Study site
    Tufts Medical Center
    Registry record
    NCT06047379 · updated
  29. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Dana Farber Cancer Institute
    Registry record
    NCT06128551 · updated
  30. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT06445062 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Ask about studies near Boston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 415-5976

or send a short form

How should we reach you?

Call